中国同辐:2024年实现营业收入75.7亿元,同比增长14.2%

市场资讯
24 Apr

来源:Gangtise投研中国同辐(01763.HK)2024年度业绩发布会:中国同辐,作为国内最大的诊断和治疗放射性药物供应商及医用钴-60源独家制造商,2024年实现营业收入75.7亿元,同比增长14.2%,净利润8.8亿元,同比增长13.3%,归母净利润4.1亿元,同比增长9.6%。公司业务涵盖核医学、放疗系统、工业辐射源等领域,提供全方位医疗解决方案。未来,随着技术创新、市场容量扩大、行业...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10